Allakos Inc
NASDAQ:ALLK

Watchlist Manager
Allakos Inc Logo
Allakos Inc
NASDAQ:ALLK
Watchlist
Price: 1.27 USD 5.83% Market Closed
Market Cap: 113.5m USD
Have any thoughts about
Allakos Inc?
Write Note

Allakos Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Allakos Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Allakos Inc
NASDAQ:ALLK
Depreciation & Amortization
$4.4m
CAGR 3-Years
42%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Depreciation & Amortization
$8.4B
CAGR 3-Years
-1%
CAGR 5-Years
34%
CAGR 10-Years
27%
Gilead Sciences Inc
NASDAQ:GILD
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Depreciation & Amortization
$5.6B
CAGR 3-Years
18%
CAGR 5-Years
23%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Depreciation & Amortization
$219.7m
CAGR 3-Years
22%
CAGR 5-Years
17%
CAGR 10-Years
13%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Depreciation & Amortization
$469.5m
CAGR 3-Years
20%
CAGR 5-Years
19%
CAGR 10-Years
25%
No Stocks Found

Allakos Inc
Glance View

Market Cap
113.5m USD
Industry
Biotechnology

Allakos, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Redwood City, California and currently employs 192 full-time employees. The company went IPO on 2018-07-19. The firm is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. The company is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. The company also developed a formulation of lirentelimab for subcutaneous (SC) administration. The firm is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.

ALLK Intrinsic Value
1.04 USD
Overvaluation 18%
Intrinsic Value
Price

See Also

What is Allakos Inc's Depreciation & Amortization?
Depreciation & Amortization
4.4m USD

Based on the financial report for Sep 30, 2024, Allakos Inc's Depreciation & Amortization amounts to 4.4m USD.

What is Allakos Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
30%

Over the last year, the Depreciation & Amortization growth was -28%. The average annual Depreciation & Amortization growth rates for Allakos Inc have been 42% over the past three years , 30% over the past five years .

Back to Top